Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zirconium Zr 89-Df-IAB2M

A radioimmunoconjugate comprised of an antibody fragment (IAB2M) against prostate-specific membrane antigen (PSMA), conjugated to the chelator desferrioxamine (Df) and labeled with the radioisotope zirconium Zr 89, with potential positron emission tomography (PET) imaging activity. Upon administration of zirconium Zr 89-Df-IAB2M, the antibody moiety binds to the extracellular domain of PSMA expressed on cancer cells. This may enable PET detection of the radioisotope moiety, and allows the imaging and quantification of PSMA-expressing tumor cells. PSMA is a cell surface peptidase highly expressed by malignant prostate epithelial cells and vascular endothelial cells in various solid tumor malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[89Zr]Df-IAB2M
zirconium Zr 89 Df-IAB2M
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search